Literature DB >> 34231051

Non-invasive assessment of liver abnormalities in pediatric Fontan patients.

Ruth De Bruyne1, Kristof Vandekerckhove2, Hazel Van Overschelde3, Fabian Hendricx4, Caroline Vande Walle5, Katya De Groote2, Joseph Panzer2, Daniel De Wolf2, Stephanie Van Biervliet6, Thierry Bové7, Katrien François7.   

Abstract

Liver abnormalities are well known among long-term survivors of Fontan palliation, which remains the definite surgery for complex congenital heart disease and single ventricle physiology. Pediatric data however are scarce. We assessed the prevalence and degree of liver abnormalities in pediatric Fontan patients through non-invasive investigations suitable for longitudinal follow-up. Thirty-five patients with a median age of 11.8 years (5.2-16.6) and median time since Fontan of 6 years (1.17-13.83) were studied. Each child underwent a blood test, liver Doppler ultrasound (US), and transient elastography (TE). Healthy children were used as controls for TE measurement. AST, ALT, γGT, and direct bilirubin were abnormal in respectively 12 (34%), 5 (14%), 24 (69%), and 7 (20%) patients, while platelet count was decreased in 7 (20%). Splenomegaly was present in 7 (20%) patients. Portal vein mean flow velocity was < 15 cm/s in 19 (54%) patients indicative of portal hypertension. Twenty-two patients (63%) showed inferior vena cava collapsibility index values below 17%, indicating venous congestion. Hepatic artery and superior mesenteric artery resistance index were inversely correlated with time post Fontan (p < 0.05). TE values in Fontan patients were significantly higher than controls, with a median of 12.6 versus 4.6 kPa (p < 0.001) and were already increased shortly after Fontan completion. 
Conclusion: Liver abnormalities are frequently observed in pediatric Fontan patients. The non-invasive investigations used were not able to confirm liver fibrosis or differentiate hepatic congestion from fibrosis. Based on our findings, we propose a prospective screening protocol with serial measurements of laboratory, (Doppler) US, and TE parameters. What is Known: • Hepatic dysfunction is a well-known consequence of the Fontan circulation. • The natural history of Fontan-associated liver disease in the pediatric age group remains unclear. What is New: • Liver abnormalities are frequently observed in pediatric Fontan patients; however, differentiating liver fibrosis and hepatic congestion with non-invasive investigations remains challenging. Sonographic Doppler measurements may improve our insight in both Fontan-associated liver disease development and the functioning of the Fontan circulation. • A prospective screening protocol is proposed to improve our ability to detect Fontan-associated liver disease early on and understand its natural history.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Children; Fontan; Fontan-associated liver disease; Liver; Non-invasive assessment

Mesh:

Year:  2021        PMID: 34231051     DOI: 10.1007/s00431-021-04163-3

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  1 in total

1.  Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model.

Authors:  Xavier Forns; Sergi Ampurdanès; Josep M Llovet; John Aponte; Llorenç Quintó; Eva Martínez-Bauer; Miquel Bruguera; Jose Maria Sánchez-Tapias; Juan Rodés
Journal:  Hepatology       Date:  2002-10       Impact factor: 17.425

  1 in total
  2 in total

1.  Risk factors for Fontan-associated hepatocellular carcinoma.

Authors:  Tomomi Kogiso; Takaomi Sagawa; Makiko Taniai; Eriko Shimada; Kei Inai; Tokuko Shinohara; Katsutoshi Tokushige
Journal:  PLoS One       Date:  2022-06-17       Impact factor: 3.752

2.  Noninvasive Pediatric Liver Fibrosis Measurement: Two-Dimensional Shear Wave Elastography Compared With Transient Elastography.

Authors:  Léa Chantal Tran; Delphine Ley; Gurvan Bourdon; Stéphanie Coopman; Héloïse Lerisson; Céline Tillaux; Hélène Béhal; Frédéric Gottrand; Madeleine Aumar
Journal:  Front Pediatr       Date:  2022-04-28       Impact factor: 3.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.